Complement-C1 inhibitor protein (Octapharma)
- Generic Name
- Complement-C1 inhibitor protein (Octapharma)
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 124
- Registration Number
- NCT06361537
- Locations
- 🇺🇦
Octapharma Research Site, Lviv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath